These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 3330140)

  • 1. Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia.
    Fraser RC; Davis RH; Walker FS
    J R Coll Gen Pract; 1987 Sep; 37(302):409-11. PubMed ID: 3330140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azapropazone or allopurinol in the treatment of chronic gout and/or hyperuricaemia. A preliminary report.
    Templeton JS
    Br J Clin Pract; 1982 Oct; 36(10):353-8. PubMed ID: 7171423
    [No Abstract]   [Full Text] [Related]  

  • 3. Preliminary studies with azapropazone in gout and hyperuricaemia.
    Thomas AL; Majoos FL; Nuki G
    Eur J Rheumatol Inflamm; 1983; 6(2):149-54. PubMed ID: 6673978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azapropazone--a treatment for hyperuricaemia and gout?
    Gibson T; Simmonds HA; Armstrong RD; Fairbanks LD; Rodgers AV
    Br J Rheumatol; 1984 Feb; 23(1):44-51. PubMed ID: 6697072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent control of hyperuricemia in the treatment of gout.
    Bull PW; Scott JT
    J Rheumatol; 1989 Sep; 16(9):1246-8. PubMed ID: 2681764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Azapropazone versus indomethacin in a double blind test with patients with ankylosing spondylitis].
    Sadowska-Wroblewska M; Garwolinska H; Filipovicz-Sosnowska A
    Z Rheumatol; 1980; 39(11-12):406-11. PubMed ID: 7282105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial.
    Taylor TH; Mecchella JN; Larson RJ; Kerin KD; Mackenzie TA
    Am J Med; 2012 Nov; 125(11):1126-1134.e7. PubMed ID: 23098865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.
    Prescrire Int; 2009 Apr; 18(100):63-5. PubMed ID: 19585722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia].
    Matzkies F
    Med Klin (Munich); 1992 Sep; 87(9):460-2. PubMed ID: 1406482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
    N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of azapropazone and indomethacin in the treatment of rheumatoid arthritis.
    Thune S
    Curr Med Res Opin; 1976; 4(1):70-5. PubMed ID: 770083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gout and hyperuricaemia.
    Faragher RI; Caelli DJ
    Aust Fam Physician; 1987 Jun; 16(6):843-4, 848. PubMed ID: 3499887
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effect of Prolixan 300 (Azapropazone) on the course of rheumatoid disease and degenerative joint disease. Comparison with indomethacin by means of a double blind test].
    Kawenoki-Minc E; Gburek Z; Sadkiewicz S; Keller B; Piotrowska E; Rajpert D; Reszkowska H
    Reumatologia; 1979; 17(3):365-74. PubMed ID: 390661
    [No Abstract]   [Full Text] [Related]  

  • 16. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
    Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
    Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
    Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.
    Hanvivadhanakul P; Akkasilpa S; Deesomchok U
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S40-7. PubMed ID: 12188443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative pilot study of azapropazone and indomethacin in the treatment of psoriatic arthritis and Reiter's disease.
    Lassus A
    Curr Med Res Opin; 1976; 4(1):65-9. PubMed ID: 770082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
    Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.